Skyrizi Prior Authorization for Oncology: Navigating Off-Label Biologic Requests

While Skyrizi (risankizumab) is primarily indicated for inflammatory conditions, navigating a Skyrizi prior authorization for oncology requires a deep understanding of off-label use protocols and payer policies for biologics.

Oncology prior authorization is among the most intricate in healthcare, characterized by high-cost biologics, frequent regimen changes, and a critical need for rapid approval. For drugs like Skyrizi, whose approved indications do not include oncology, the PA process introduces additional layers of complexity, primarily around medical necessity and off-label use documentation. Klivira provides the automation and policy logic to manage these nuanced workflows.

Skyrizi (Risankizumab): Mechanism and Approved Indications

Skyrizi (risankizumab) is an interleukin-23 (IL-23) inhibitor, a biologic medication developed by AbbVie. Its approved indications include plaque psoriasis, psoriatic arthritis, and Crohn's disease. These indications are distinct from typical oncology treatment pathways, meaning any request for Skyrizi in an oncology setting would be considered off-label and subject to specific payer scrutiny.

The Challenge of Biologic Prior Authorization in Oncology

Oncology care frequently involves high-cost biologics and immunotherapies, often triggering extensive prior authorization requirements. These include J-code chemotherapy and biologic infusions, advanced imaging for staging, and supportive care medications. Each regimen change or new line of therapy typically initiates a new PA event, leading to dozens of PA cycles per patient over a treatment course, demanding robust automation and tracking.

Considerations for Off-Label Biologic Use in Oncology PA

When a biologic like Skyrizi is requested for an oncology indication outside its FDA-approved label, payers typically require support from recognized compendia. The NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium are dominant medical-necessity frameworks for oncology PA. Payer policies vary on which compendium categories (e.g., Category 1, 2A, 2B) they accept for off-label use, making precise documentation critical.

Documentation Requirements for Off-Label Oncology Biologics

**Diagnosis Confirmation:** Pathology report with histology, tumor staging (AJCC TNM), and relevant molecular markers (e.g., EGFR, ALK, PD-L1, MSI/MMR).
**Prior-Line Treatment Response:** Documentation of previous regimens, response duration, and clear rationale for the proposed next-line therapy.
**Performance Status:** ECOG or Karnofsky score to support patient fitness for the requested treatment.
**Compendium Citation:** Specific reference to the NCCN Compendium (or other payer-accepted compendium) for the requested off-label indication, tumor type, and clinical context.
**Comorbidities and Contraindications:** Relevant organ function assessments or prior toxicities that justify the chosen regimen.

Common Denial Reasons for Off-Label Oncology Biologics

Denials for off-label biologic requests in oncology often stem from a lack of compendium support, where the requested drug is not listed or is in a category not accepted by the payer for that specific tumor type or line of therapy. Other common reasons include step therapy requirements for less costly alternatives, or documentation gaps such as missing molecular marker results or insufficient rationale for regimen change. NCD/LCD non-coverage for Medicare Advantage plans can also be a factor.

Klivira's Role in Streamlining Complex Oncology PAs

Klivira's prior authorization automation platform is designed to manage the complexities of oncology PA. Our system incorporates NCCN-compendium-aware policy logic to flag required documentation for specific regimens and tumor types. We facilitate regimen-level PA workflows, manage the split between medical and pharmacy benefit drugs (e.g., X12 278 for medical benefit, ePA for pharmacy benefit), and provide concurrent PA tracking for the numerous events over a patient's treatment course. This ensures that even challenging off-label requests are processed with maximum efficiency and accuracy.

Frequently asked questions

Is Skyrizi (risankizumab) commonly used in oncology treatment?

No, Skyrizi (risankizumab) is an IL-23 inhibitor primarily indicated for inflammatory conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease. Its use in oncology is not part of its FDA-approved label and would be considered off-label, requiring specific medical necessity documentation and compendium support.

What are the key documentation requirements for off-label biologic prior authorization in oncology?

For off-label biologic prior authorizations in oncology, payers typically require comprehensive documentation including diagnosis confirmation (pathology, staging), detailed rationale for the proposed regimen, prior-line treatment history, patient performance status, and a specific citation from a recognized compendium like the NCCN Drugs & Biologics Compendium to support medical necessity.

How does Klivira handle off-label prior authorization requests for biologics in oncology?

Klivira's platform incorporates NCCN-compendium-aware policy logic to identify and guide the submission of necessary documentation for off-label requests. Our automation helps ensure that all required clinical data, compendium citations, and payer-specific criteria are met, streamlining the submission process and reducing the likelihood of denials for documentation gaps.

What is the role of the NCCN Compendium in oncology prior authorization?

The NCCN Drugs & Biologics Compendium serves as a critical medical-necessity framework for oncology prior authorization, especially for off-label drug use. Payers frequently reference the Compendium's categories (e.g., Category 1, 2A, 2B) to determine coverage for drugs used outside their FDA-approved indications. Compliance with these guidelines is essential for approval.

How do medical benefit and pharmacy benefit impact oncology drug prior authorization?

Oncology drugs can fall under either the medical benefit (e.g., J-coded IV infusions) or the pharmacy benefit (e.g., oral oncolytics). This split dictates the PA pathway: medical benefit PAs typically route via provider portals or X12 278 transactions, while pharmacy benefit PAs route through payer PBMs and ePA partners like CoverMyMeds or Surescripts. Klivira manages both routing mechanisms.